Literature DB >> 12517643

Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival.

Margaret L J Davy1, Tom J Dodd, Colin G Luke, David M Roder.   

Abstract

OBJECTIVE: To investigate survivals from cervical cancer, with special reference to effects of glandular histology and its influence on prognostic characteristics and management decisions.
METHODS: Data on cervical cancers, diagnosed in 1984-2000, were obtained from the gynecologic oncology registry of hospitals of the University of Adelaide. Comparisons were made of disease-specific survival, age at diagnosis, diagnostic period, stage, grade, and primary course of treatment.
RESULTS: The study included 544 squamous cell carcinomas, 43 adenosquamous carcinomas, five clear cell cancers, 136 other adenocarcinomas, and 19 cancers of "other" histological type. Overall survival was 72.2% at 5 years from diagnosis, decreasing to 67.5% at 15 years. Survival was lower for older ages, higher grades, and higher International Federation of Gynecology and Obstetrics stages, although equivalent for stages IIA and IIB. Unadjusted survivals varied by histological type (P =.001), with lower survivals suggested for adenosquamous and clear cell lesions and "other" histological types than for squamous cell carcinomas and other adenocarcinomas. After adjusting for age, stage, grade, and diagnostic period, adenocarcinomas had a higher case fatality than squamous cell lesions (relative risk 2.08, 95% confidence limit 1.35, 3.21), whereas the elevation in relative risk was lower and not statistically significant for a combined adenosquamous and clear cell category at 1.25 (0.69, 2.24). For stage II, both adenocarcinomas and the adenosquamous and clear cell group had lower survivals than squamous cell cancers.
CONCLUSION: Relative to squamous cell carcinomas, adenocarcinomas and potentially adenosquamous cancers are becoming more common. This has implications for screening, treatment, and prognosis.

Entities:  

Mesh:

Year:  2003        PMID: 12517643     DOI: 10.1016/s0029-7844(02)02275-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

1.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

Review 2.  Adenocarcinoma of the cervix: should we treat it differently?

Authors:  Ned L Williams; Theresa L Werner; Elke A Jarboe; David K Gaffney
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

Review 3.  Adenocarcinoma of the uterine cervix: why is it different?

Authors:  Keiichi Fujiwara; Bradley Monk; Mojgan Devouassoux-Shisheboran
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

Review 4.  Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

Authors:  Susan J Keam; Diane M Harper
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Authors:  Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger
Journal:  Int J Cancer       Date:  2019-05-06       Impact factor: 7.316

6.  The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions.

Authors:  G Terry; L Ho; P Londesborough; P Cross; A Lopes; J Monaghan; J Cuzick
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

7.  Intraoperative radiotherapy in stage IIB adenocarcinoma of the uterine cervix: a retrospective study.

Authors:  Ying Gao; Zi Liu; Fei Gao; Xi Chen
Journal:  Onco Targets Ther       Date:  2013-11-20       Impact factor: 4.147

8.  Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.

Authors:  Jeanne M Pimenta; Claudia Galindo; David Jenkins; Sylvia M Taylor
Journal:  BMC Cancer       Date:  2013-11-21       Impact factor: 4.430

9.  Glucose-regulated protein 58 modulates β-catenin protein stability in a cervical adenocarcinoma cell line.

Authors:  Chia-Jung Liao; Tzu-I Wu; Ya-Hui Huang; Ting-Chang Chang; Chyong-Huey Lai; Shih-Ming Jung; Chuen Hsueh; Kwang-Huei Lin
Journal:  BMC Cancer       Date:  2014-08-01       Impact factor: 4.430

10.  Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?

Authors:  Alejandra Castanon; Rebecca Landy; Peter D Sasieni
Journal:  Int J Cancer       Date:  2016-05-06       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.